Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2026 05:37 ET | Source: Research and Markets

APT-1011 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "APT-1011 Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The APT-1011 market report provides...
May 15, 2026 05:33 ET | Source: Research and Markets

Tradipitant Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Tradipitant Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report offers insights into...
May 14, 2026 09:45 ET | Source: Research and Markets

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Inhibitors by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
May 14, 2026 09:26 ET | Source: Research and Markets

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Therapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
May 12, 2026 11:46 ET | Source: Research and Markets

$16.8 Billion Targeted Cancer Therapy Market Report 2026-2031: Revenue to Grow by Nearly $10 Billion Over the Forecast Period

Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Targeted Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F" has been added to ResearchAndMarkets.com's...
May 07, 2026 07:34 ET | Source: Research and Markets

IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "IgG4-Related Disease Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
May 04, 2026 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis

New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity KNOXVILLE, Tenn., May ...
April 30, 2026 12:19 ET | Source: Research and Markets

Contract Research and Manufacturing Services (CRAMS) Research Report 2026: $258.36 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 30, 2026 (GLOBE NEWSWIRE) -- The "Contract Research and Manufacturing Services (CRAMS) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Contract...
April 30, 2026 07:05 ET | Source: AC Immune SA

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy...
April 30, 2026 07:00 ET | Source: AC Immune SA

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12...